Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 186

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response

Open access
Caruso, Stefano, Calatayud, Anna-Line, Pilet, Jill, La Bella, Tiziana, Rekik, Samia, Imbeaud, Sandrine, Letouzé, Eric, Meunier, Léa, Bayard, Quentin, Rohr-Udilova, Nataliya, Péneau, Camille, Grasl-Kraupp, Bettina, de Koning, Leanne, Ouine, Bérengère, Bioulac-Sage, Paulette, Couchy, Gabrielle, Calderaro, Julien, Nault, Jean-Charles, Zucman-Rossi, Jessica, Rebouissou, Sandra · 2019 · Gastroenterology

Abstract

BACKGROUND AND AIMS: Hepatocellular carcinomas (HCCs) are heterogeneous aggressive tumors with low rates of response to treatment at advanced stages. We screened a large panel of liver cancer cell lines (LCCLs) to identify agents that might be effective against HCC and markers of therapeutic response. METHODS: We performed whole-exome RNA and microRNA sequencing and quantification of 126 proteins in 34 LCCLs. We screened 31 anticancer agents for their ability to decrease cell viability. We compared genetic, RNA, and protein profiles of LCCLs with those of primary HCC samples and searched for markers of response. RESULTS: The protein, RNA and mutational signatures of the LCCLs were similar to those of the proliferation class of HCC, which is the most aggressive tumor type. Cell lines with alterations in genes encoding members of the Ras-MAPK signaling pathway and that required fibroblast growth factor (FGF)19 signaling via FGF receptor 4 for survival were more sensitive to trametinib than to FGF receptor 4 inhibitors. Amplification of FGF19 resulted in increased activity of FGF19 only in tumor cells that kept a gene expression pattern of hepatocyte differentiation. We identified single agents and combinations of agents that reduced viability of cells with features of the progenitor subclass of HCC. LCCLs with inactivating mutations in TSC1 and TSC2 were sensitive to the mammalian target of rapamycin inhibitor rapamycin, and cells with inactivating mutations in TP53 were sensitive to the Aurora kinase A inhibitor alisertib. Amplification of MET was associated with hypersensitivity to cabozantinib and the combination of sorafenib and inhibitors of MAP kinase 1 and MAP kinase2 had a synergistic antiproliferative effect. CONCLUSION: LCCLs can be screened for drugs and agents that might be effective for treatment of HCC. We identified genetic alterations and gene expression patterns associated with response to these agents. This information might be used to select patients for clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2019.05.001

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 186

Metadata

Authors
Caruso, S., Calatayud, A.-L., Pilet, J., La Bella, T., Rekik, S., Imbeaud, S., Letouzé, E., Meunier, L., Bayard, Q., Rohr-Udilova, N., Péneau, C., Grasl-Kraupp, B., de Koning, L., Ouine, B., Bioulac-Sage, P., Couchy, G., Calderaro, J., Nault, J.-C., Zucman-Rossi, J., & Rebouissou, S.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2019-09
Volume
157
Issue
3
Pages
760-776
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2942698941
Cited by
186
References
6
FWCI
15.05
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. https://app.cochat.ai/papers/10.1053/j.gastro.2019.05.001
The paper
Caruso, S., Calatayud, A.-L., Pilet, J., La Bella, T., Rekik, S., Imbeaud, S., Letouzé, E., Meunier, L., Bayard, Q., Rohr-Udilova, N., Péneau, C., Grasl-Kraupp, B., de Koning, L., Ouine, B., Bioulac-Sage, P., Couchy, G., Calderaro, J., Nault, J.-C., Zucman-Rossi, J., & Rebouissou, S. (2019). Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.05.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.